RASL12

Across TCGA pan-cancer cohorts, RASL12 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RASL12 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RASL12 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RASL12 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, PDAC, and GBM are the cancer types where RASL12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.876	0.277	.005	26	view →
PDAC	OS	Quartile	All	0.276	0.702	.014	8	view →
GBM	DFS	Median	All	0.562	0.790	.010	7	view →
UCEC	OS	Quartile	II,III,IV	0.520	1.000	.033	4	view →
LSCC	DFS	Median	All	0.896	0.976	.033	2	view →
LUAD	DFS	Quartile	All	0.711	0.413	.026	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RASL12–CCRCC (DFS)

Open the CCRCC breakdown →